Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
IBD
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - IBD
    FDA: TNF Blockers Increase Risk of Invasive Fungal Infections, Delayed Treatment Can Result in Death - (DGNews)
    TopAbstracts in IBD 09/02/2008 - (DGNews)
    Consumption of Nuts, Corn Does Not Increase Risk of Diverticulosis in Men - (DGNews)
    TopAbstracts in IBD 08/19/2008 - (DGNews)
    TopAbstracts in IBD 08/05/2008 - (DGNews)

    News archive

     Recent webcasts/CME - IBD
    • State of the Science in IBS-C and Other Constipation-Related Disorders: Where Are We Now, and Where Are We Going?
    • Managing IBS-C and Other Constipation-Related Disorders: Where Are We Now?
    • Managing IBS-C and Other Constipation-Related Disorders: Where Are We Going?
    • Achieving Clinical Remission in Patients With Crohn's Disease: An Update of Recent Data
    • Therapeutic Options for Inflammatory Bowel Disease

      Webcasts/CME archive

       Recent cases - IBD
        Sweet's Syndrome in a Patient with Crohn's Disease: A Case Report
        Stroke in Inflammatory Bowel Disease: A Report of Two Cases and Review of the Literature
        Colonic Perforation Following Mild Abdominal Trauma in a Patient with Crohn's Disease: A Case Report
        Takayasu's Arteritis Associated wWith Crohn's Disease: A Case Report
        Granulomatous Cheilitis Associated with Exacerbations of Crohn's Disease: A Case Report

        Cases archive
          




        my personal edition > ibd > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        MMX Mesalazine Therapy Relieves Ulcerative Colitis Symptoms: Presented at UEGW

        By Jill Stein

        PARIS, FRANCE -- October 29, 2007 -- MMX(TM) mesalazine provides resolution of rectal bleeding and high stool frequency in patients with ulcerative colitis (UC) within weeks of treatment initiation, researchers reported here at the 15th United European Gastroenterology Week (UEGW).

        Stefan Schreiber, MD, Professor of Medicine and Gastroenterology, Christian Albrechts Kiel University, Keil, Germany, and colleagues examined the time to initial resolution of rectal bleeding and normalisation of stool frequency in patients with mild to moderate UC who received MMX mesalazine (2.4 g/day or 4/8 g/day) or placebo for 8 weeks.

        The data were drawn from a pooled analysis of two phase 3 studies that had almost identical study designs and endpoints. A total of 517 patients were included in the intent-to-treat population.

        For the initial normalisation of stool frequency alone, median times were 19 days in the MMX mesalazine 2.4 g/day group and 20 days in the 4.8 g/day group, which was significantly shorter compared with the 34 days in the placebo group (P =.00001).

        For the initial resolution of rectal bleeding alone, median times were also significantly shorter in the MMX mesalazine groups compared with the placebo group (7 days, 8 days, and 16 days in the three groups, respectively).

        Median time to initial resolution of symptoms was significantly shorter in the MMX mesalazine groups compared with the placebo group (25 days, 26 days, and 44 days, respectively (P =.0001).

        Mean stool frequency and rectal bleeding scores decreased after treatment in all three groups; however, the changes in symptom scores were largest in the two MMX mesalazine groups.

        Overall, the results showed that in most patients receiving MMX mesalazine, resolution of both major UC symptoms (as defined in this analysis) occurred within 4 weeks of therapy versus greater than 6 weeks for placebo, Dr. Schreiber said.

        MMX mesalazine is a novel, once-daily, high-strength formulation of 5-aminosalicyclic acid (mesalazine, 1.2 g per tablet) that uses MMX technology to deliver 5-ASA throughout the colon. This delivery system uses lipophilic and hydrophilic excipients, which are believed to prolong exposure of the colonic mucosa to the 5-aminosalicyclic acid, enclosed within a gastro-resistant, pH-dependent coating.

        Funding for this study was provided by Shire Pharmaceuticals.


        [Presentation Title: MMXTM Mesalazine Therapy for Active, Mild-to-Moderate Ulcerative Colitis: Time to Initial Symptom Resolution. Abstract Number G-359]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send